The Patent Finder
SZ

Simcere Zaiming Pharmaceutical Co., Ltd.

First filing 2023
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Two patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2043. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2043
Next term end
2
Patent families

When these terms end

Each bar runs from grant to computed term end. 2026 to 2043.
US 12,760,098 Humanized CD19 Antibody and Use Thereof Sep 4, 2043
US 12,799,201 ANTI-CD22 Nano Antibody and Use Thereof Sep 25, 2043
20302034203820422043
25 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

  • 2 of the patents on this record were granted since Aug 20, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 2 of 2

PatentTitleStatusExpiresConfidence
US 12,760,098Humanized CD19 Antibody and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,799,201ANTI-CD22 Nano Antibody and Use Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 2: 25 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited